Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederik F Kreiner

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Diabetologia|February 17, 2021
Current and future therapies for type 1 diabetesBernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, et al.
Biomedicines|September 28, 2023
Obesity-Related Kidney Disease: Current Understanding and Future PerspectivesFrederik F Kreiner, Philip Andreas Schytz, Hiddo J L Heerspink, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trialsThomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trialsAnna R Kahkoska, Milan S Geybels, Klara R Klein, et al.
Clinical Immunology (Orlando, Fla.)|September 9, 2022
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetesBurcak Yesildag, Joan Mir-Coll, Aparna Neelakandhan, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Diabetologia|February 17, 2021
Current and future therapies for type 1 diabetesBernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, et al.
Biomedicines|September 28, 2023
Obesity-Related Kidney Disease: Current Understanding and Future PerspectivesFrederik F Kreiner, Philip Andreas Schytz, Hiddo J L Heerspink, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trialsThomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trialsAnna R Kahkoska, Milan S Geybels, Klara R Klein, et al.
Clinical Immunology (Orlando, Fla.)|September 9, 2022
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetesBurcak Yesildag, Joan Mir-Coll, Aparna Neelakandhan, et al.
Pageof 1